Dr. Seth Toback, Senior Vice President of Global Medical Affairs at Novavax, will present on "Local and systemic reactogenicity after mRNA and protein-based #COVID vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomised phase 2 trial (COV-BOOST)."…
pic.twitter.com/nGkK1WI8jd